Cabergoline and Osteoporosis - a phase IV clinical study of FDA data

Summary:

Osteoporosis is reported as a side effect among people who take Cabergoline (cabergoline), especially for people who are female, 60+ old, also take Gliclazide, and have Acromegaly.

The phase IV clinical study analyzes which people have Osteoporosis when taking Cabergoline. It is created by eHealthMe based on reports of 5,946 people who have side effects when taking Cabergoline from the FDA, and is updated regularly.

What is Cabergoline?

Cabergoline has active ingredients of cabergoline. It is often used in prolactinoma. eHealthMe is studying from 6,257 Cabergoline users. Check the latest studies of Cabergoline.

What is Osteoporosis?

Osteoporosis (bones weak and more likely to break) is found to be associated with 1,807 drugs and 1,904 conditions by eHealthMe. Check the latest studies of Osteoporosis.

On Aug, 02, 2026

5,946 people reported to have side effects when taking Cabergoline.
Among them, 50 people (0.84%) have Osteoporosis.

Among these 50 people:

What is the gender of people who have Osteoporosis when taking Cabergoline? *

female: 88 %
male: 12 %

What is the age of people who have Osteoporosis when taking Cabergoline? *

What are other drugs people take besides Cabergoline? *

What are other side effects people have besides Osteoporosis? *

Gallstones (stone formation by bile component): 30 people, 60.00%
Weight Decreased: 28 people, 56.00%
Dizziness: 27 people, 54.00%
Fatigue (feeling of tiredness): 27 people, 54.00%
Stress And Anxiety: 27 people, 54.00%
Memory Loss: 27 people, 54.00%
High Blood Pressure: 25 people, 50.00%
Fall: 25 people, 50.00%
Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect): 24 people, 48.00%
Skin Discoloration: 24 people, 48.00%

What are the existing conditions these people have? *

Acromegaly (body produces too much growth hormone, leading to excess growth of body tissues): 40 people, 80.00%
High Blood Pressure: 27 people, 54.00%
Type 2 Diabetes: 22 people, 44.00%
Parkinson's Disease: 14 people, 28.00%
Blood Glucose Abnormal: 6 people, 12.00%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 5 people, 10.00%
Increased Upper Airway Secretion: 4 people, 8.00%
High Blood Cholesterol: 4 people, 8.00%
Hiv Infection: 4 people, 8.00%
Sleep Disorder: 4 people, 8.00%

* Approximation only. Some reports may have incomplete information.

Do you take Cabergoline and have Osteoporosis?

- Check whether Osteoporosis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Cabergoline:

Cabergoline (6,257 reports)

Osteoporosis treatments and more:

Osteoporosis (290,734 reports)

Browse all side effects of Cabergoline:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Osteoporosis:

Osteoporosis (1,807 drugs)

Browse all the conditions that are associated with Osteoporosis:

Osteoporosis (1,904 conditions)

Related publications that referenced our studies

Gürbüz F, Ya?c?-Küpeli B, K?r Y, Yüksel B, Zorludemir S, Gürbüz BB, Küpeli S, "The first report of cabergoline-induced immune hemolytic anemia in an adolescent with prolactinoma", Journal of Pediatric Endocrinology and Metabolism, 2014 Jan .
Hirschmann S, Gibel A, Tsvelikhovsky I, Lisker A, "Late-Onset Psychosis and Risedronate Treatment for Osteoporosis: A Case Report", Clinical schizophrenia & related psychoses, 2013 May .
Ko KD, Cho BL, "Risedronate-related Localized Amnesia in an Elderly Patient with Osteoporosis", Journal of the Korean Geriatrics Society, 2012 Dec .
Lee WY, Sun LM, Lin MC, Liang JA, Chang SN, Sung FC, Muo CH, Kao CH, "A higher dosage of oral alendronate will increase the subsequent cancer risk of osteoporosis patients in Taiwan: a population-based cohort study", PloS one, 2012 Dec .
Harris YT, Harris AZ, "Cabergoline associated with first episode mania", Psychosomatics, 2012 Jan .
Hirschmann S, Gibel A, Tsvelikhovsky I, Lisker A, "Late-Onset Psychosis and Risedronate Treatment for Osteoporosis: A Case Report", Clinical schizophrenia & related psychoses, 2013 May .
Gürbüz F, Ya?c?-Küpeli B, K?r Y, Yüksel B, Zorludemir S, Gürbüz BB, Küpeli S, "The first report of cabergoline-induced immune hemolytic anemia in an adolescent with prolactinoma", Journal of Pediatric Endocrinology and Metabolism, 2014 Jan .
Ko KD, Cho BL, "Risedronate-related Localized Amnesia in an Elderly Patient with Osteoporosis", Journal of the Korean Geriatrics Society, 2012 Dec .
Lee WY, Sun LM, Lin MC, Liang JA, Chang SN, Sung FC, Muo CH, Kao CH, "A higher dosage of oral alendronate will increase the subsequent cancer risk of osteoporosis patients in Taiwan: a population-based cohort study", PloS one, 2012 Dec .
Harris YT, Harris AZ, "Cabergoline associated with first episode mania", Psychosomatics, 2012 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on cabergoline (the active ingredients of Cabergoline) and Cabergoline (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.